Search | Page 16 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. What MDS Patients Should Know About Clinical Trials

    ... approved drugs available for people with MDS. These are lenalidomide (Revlimid®), azacitidine (Vidaza®), and ... MDS -- received either azacitidine alone, azacitidine and lenalidomide, or azacitidine combined with vorinostat.  I wrote this study ...

    Interview last updated 11/13/2015 - 11:12am.

  2. Interviews with the Experts Comorbidities: When Other Medical Conditions Affect MDS Treatment

    ... on dialysis, it’s very difficult to know what dose of lenalidomide (Revlimid®) to give them because this drug is eliminated via ... with standard therapies such as azacitidine (Vidaza®) or lenalidomide (Revlimid®). The more things that are wrong with a patient, the ...

    Interview last updated 11/17/2014 - 9:31am.

  3. Interviews with the Experts Managing MDS With Supportive Care and Active Treatment

    ... agent in this group that also improves blood counts is lenalidomide (Revlimid®), but it has a different mechanism of action from ... agents and is categorized as an immunomodulatory agent. Lenalidomide has been shown to be best suited for a subset of MDS patients ...

    Interview last updated 09/22/2014 - 12:25pm.

  4. Clinical Trial Basics

    ... decitabine (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab (Soliris) azacitidine ...

    Page last updated 01/20/2015 - 4:58pm.

  5. Clinical Trial Basics

    ... decitabine (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab (Soliris) azacitidine ...

    Page last updated 01/20/2015 - 4:46pm.

  6. Lower-Risk MDS: Diagnosis and Treatment Options

    ... have a very good chance of responding to a drug called lenalidomide (Revlimid®), with about a 75% chance of becoming ... they have been needing red blood cell transfusions. Lenalidomide is a pill that is usually taken every day. If a lower-risk ...

    Interview last updated 05/18/2012 - 1:28pm.

  7. Understanding Prognosis in MDS

    ... drug treatments have been introduced since then, like lenalidomide (Revlimid®) and the hypomethylating agents—azacitidine ...

    Interview last updated 05/02/2012 - 4:36pm.

  8. Treating Higher-Risk Myelodysplastic Syndromes

    ... treatments for MDS includes azacitidine, decitabine, or lenalidomide (Revlimid®). Clinical research with new chemotherapy ...

    Interview last updated 05/18/2012 - 1:55pm.